Scholarlink

Purpose <p>In 2007, a prospective study on VEPTR treatment of EOS in children without rib abnormalities was initiated. Two-year and 5-year follow-up results from this cohort have previously demonstrated that scoliosis is controlled, and spinal growth continues. This study examines whether, at long-term follow-up, VEPTR continues to control scoliosis and allow spinal growth.</p> Methods <p>Prospective, multicenter cohort of participants with EOS without rib abnormalities who underwent VEPTR. Pre-implantation and last available images were compared, regardless of whether VEPTR remained in vivo.</p> Results <p>33 patients were available for evaluation (mean age at insertion 4.8 ± 2.5 yrs; mean f/u 10.6 ± 2.7 yrs; mean 14.6 surgeries. Currently 14 patients still have VEPTR, 17 have converted and 2 have had VEPTR explanted. On last available imaging (mean f/u 10.4 ± 1.7 yrs), scoliosis improved from 72 ± 16° preop to 61 ± 22° (<i>p</i> &lt; 0.001) and T1–T12 coronal height increased (14.5 ± 2.3 to 19.6 ± 3.9&#xa0;cm, <i>p</i> &lt; 0.001). Maximum kyphosis increased from 41 ± 19 to 62 ± 26° (<i>p</i> &lt; 0.001). T1-T12 sagittal length (cm) increased from 15.6 ± 2.3 to 20.2 ± 3.9° (<i>p</i> &lt; 0.001).</p> <p>A subset of 14 patients who still have VEPTR in vivo was analyzed: mean age at insertion was 4.6 ± 2.8 yrs, with a mean VEPTR treatment duration of 10.7 ± 3 yrs. Scoliosis improved from preop (79 ± 16 to 66 ± 23°, <i>p</i> = 0.01). T1–T12 coronal height increased (13.9 ± 2.1 to 18.5 ± 3.3&#xa0;cm, <i>p</i> = 0.001). Maximum kyphosis increased from 40 ± 28 to 66 ± 23° (<i>p</i> = 0.011). T1-T12 sagittal length (cm) increased from 15.2 ± 2.6 to 18.9 ± 3° (<i>p</i> &lt; 0.001). Thirty-one patients (93%) experienced at least 1 complication, with 93 total complications observed. Eighteen patients (54%) required at least one unplanned surgery.</p> Conclusion <p>With long-term follow up, VEPTR continues to control scoliosis and allow spinal growth. However, kyphosis increased, and most patients experienced at least one complication.</p> Level of Evidence <p>Level II—prospective cohort, therapeutic study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

VEPTR treatment of early onset scoliosis in children without rib abnormalities: 10-year follow-up from a prospective multicenter study

  • 期刊论文

  • 发表日期：

    2026年5月26日

查看全文
  • Flavia Alberghina,
  • Ron El-Hawary,
  • Kevin Morash,
  • Michael Vitale,
  • John Smith,
  • Amer Samdani,
  • John Flynn

摘要

Purpose

In 2007, a prospective study on VEPTR treatment of EOS in children without rib abnormalities was initiated. Two-year and 5-year follow-up results from this cohort have previously demonstrated that scoliosis is controlled, and spinal growth continues. This study examines whether, at long-term follow-up, VEPTR continues to control scoliosis and allow spinal growth.

Methods

Prospective, multicenter cohort of participants with EOS without rib abnormalities who underwent VEPTR. Pre-implantation and last available images were compared, regardless of whether VEPTR remained in vivo.

Results

33 patients were available for evaluation (mean age at insertion 4.8 ± 2.5 yrs; mean f/u 10.6 ± 2.7 yrs; mean 14.6 surgeries. Currently 14 patients still have VEPTR, 17 have converted and 2 have had VEPTR explanted. On last available imaging (mean f/u 10.4 ± 1.7 yrs), scoliosis improved from 72 ± 16° preop to 61 ± 22° (p < 0.001) and T1–T12 coronal height increased (14.5 ± 2.3 to 19.6 ± 3.9 cm, p < 0.001). Maximum kyphosis increased from 41 ± 19 to 62 ± 26° (p < 0.001). T1-T12 sagittal length (cm) increased from 15.6 ± 2.3 to 20.2 ± 3.9° (p < 0.001).

A subset of 14 patients who still have VEPTR in vivo was analyzed: mean age at insertion was 4.6 ± 2.8 yrs, with a mean VEPTR treatment duration of 10.7 ± 3 yrs. Scoliosis improved from preop (79 ± 16 to 66 ± 23°, p = 0.01). T1–T12 coronal height increased (13.9 ± 2.1 to 18.5 ± 3.3 cm, p = 0.001). Maximum kyphosis increased from 40 ± 28 to 66 ± 23° (p = 0.011). T1-T12 sagittal length (cm) increased from 15.2 ± 2.6 to 18.9 ± 3° (p < 0.001). Thirty-one patients (93%) experienced at least 1 complication, with 93 total complications observed. Eighteen patients (54%) required at least one unplanned surgery.

Conclusion

With long-term follow up, VEPTR continues to control scoliosis and allow spinal growth. However, kyphosis increased, and most patients experienced at least one complication.

Level of Evidence

Level II—prospective cohort, therapeutic study.